Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation
© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons..
Kidney transplantation (KT) from deceased donors with hepatitis C virus (HCV) into HCV-negative recipients has become more common. However, the risk of complications such as BK polyomavirus (BKPyV) remains unknown. We assembled a retrospective cohort at four centers. We matched recipients of HCV-viremic kidneys to highly similar recipients of HCV-aviremic kidneys on established risk factors for BKPyV. To limit bias, matches were within the same center. The primary outcome was BKPyV viremia ≥1000 copies/ml or biopsy-proven BKPyV nephropathy; a secondary outcome was BKPyV viremia ≥10 000 copies/ml or nephropathy. Outcomes were analyzed using weighted and stratified Cox regression. The median days to peak BKPyV viremia level was 119 (IQR 87-182). HCV-viremic KT was not associated with increased risk of the primary BKPyV outcome (HR 1.26, p = .22), but was significantly associated with the secondary outcome of BKPyV ≥10 000 copies/ml (HR 1.69, p = .03). One-year eGFR was similar between the matched groups. Only one HCV-viremic kidney recipient had primary graft loss. In summary, HCV-viremic KT was not significantly associated with the primary outcome of BKPyV viremia, but the data suggested that donor HCV might elevate the risk of more severe BKPyV viremia ≥10 000 copies/ml. Nonetheless, one-year graft function for HCV-viremic recipients was reassuring.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 22(2022), 2 vom: 01. Feb., Seite 599-609 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Molnar, Miklos Z [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.04.2022 Date Revised 03.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ajt.16834 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331547295 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331547295 | ||
| 003 | DE-627 | ||
| 005 | 20240303231819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ajt.16834 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1315.xml |
| 035 | |a (DE-627)NLM331547295 | ||
| 035 | |a (NLM)34613666 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Molnar, Miklos Z |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2022 | ||
| 500 | |a Date Revised 03.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The American Society of Transplantation and the American Society of Transplant Surgeons. | ||
| 520 | |a Kidney transplantation (KT) from deceased donors with hepatitis C virus (HCV) into HCV-negative recipients has become more common. However, the risk of complications such as BK polyomavirus (BKPyV) remains unknown. We assembled a retrospective cohort at four centers. We matched recipients of HCV-viremic kidneys to highly similar recipients of HCV-aviremic kidneys on established risk factors for BKPyV. To limit bias, matches were within the same center. The primary outcome was BKPyV viremia ≥1000 copies/ml or biopsy-proven BKPyV nephropathy; a secondary outcome was BKPyV viremia ≥10 000 copies/ml or nephropathy. Outcomes were analyzed using weighted and stratified Cox regression. The median days to peak BKPyV viremia level was 119 (IQR 87-182). HCV-viremic KT was not associated with increased risk of the primary BKPyV outcome (HR 1.26, p = .22), but was significantly associated with the secondary outcome of BKPyV ≥10 000 copies/ml (HR 1.69, p = .03). One-year eGFR was similar between the matched groups. Only one HCV-viremic kidney recipient had primary graft loss. In summary, HCV-viremic KT was not significantly associated with the primary outcome of BKPyV viremia, but the data suggested that donor HCV might elevate the risk of more severe BKPyV viremia ≥10 000 copies/ml. Nonetheless, one-year graft function for HCV-viremic recipients was reassuring | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a JC | |
| 650 | 4 | |a clinical research | |
| 650 | 4 | |a infection and infectious agents - viral: BK | |
| 650 | 4 | |a infection and infectious agents - viral: hepatitis C | |
| 650 | 4 | |a infectious disease | |
| 650 | 4 | |a kidney transplantation | |
| 650 | 4 | |a nephrology | |
| 650 | 4 | |a polyoma | |
| 650 | 4 | |a practice | |
| 700 | 1 | |a Potluri, Vishnu S |e verfasserin |4 aut | |
| 700 | 1 | |a Schaubel, Douglas E |e verfasserin |4 aut | |
| 700 | 1 | |a Sise, Meghan E |e verfasserin |4 aut | |
| 700 | 1 | |a Concepcion, Beatrice P |e verfasserin |4 aut | |
| 700 | 1 | |a Forbes, Rachel C |e verfasserin |4 aut | |
| 700 | 1 | |a Blumberg, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Bloom, Roy D |e verfasserin |4 aut | |
| 700 | 1 | |a Shaffer, David |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Raymond T |e verfasserin |4 aut | |
| 700 | 1 | |a Strohbehn, Ian A |e verfasserin |4 aut | |
| 700 | 1 | |a Elias, Nahel |e verfasserin |4 aut | |
| 700 | 1 | |a Azhar, Ambreen |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Mital |e verfasserin |4 aut | |
| 700 | 1 | |a Sawinski, Deirdre |e verfasserin |4 aut | |
| 700 | 1 | |a Binari, Laura A |e verfasserin |4 aut | |
| 700 | 1 | |a Talwar, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Balaraman, Vasanthi |e verfasserin |4 aut | |
| 700 | 1 | |a Bhalla, Anshul |e verfasserin |4 aut | |
| 700 | 1 | |a Eason, James D |e verfasserin |4 aut | |
| 700 | 1 | |a Besharatian, Behdad |e verfasserin |4 aut | |
| 700 | 1 | |a Trofe-Clark, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Goldberg, David S |e verfasserin |4 aut | |
| 700 | 1 | |a Reese, Peter P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons |d 2001 |g 22(2022), 2 vom: 01. Feb., Seite 599-609 |w (DE-627)NLM119667924 |x 1600-6143 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:2 |g day:01 |g month:02 |g pages:599-609 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ajt.16834 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 2 |b 01 |c 02 |h 599-609 | ||